Search research articles
Contact Us
Filters
Showing results (191-200 of 211) with videos related to
Page
of 22
Sort By:
Nature Medicine
|
March 30, 2026
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial
Zev A Wainberg, Gulam A Manji, Nathan Bahary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2021
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H Hanna, Andrew G Robinson, Sarah Temin, et al.
Clinical Lung Cancer
|
May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
Fred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
Navneet Singh, Sarah Temin, Sherman Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
Navneet Singh, Sarah Temin, Sherman Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
David E Gerber, Jeffrey R Infante, Michael S Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready, Matthew D Hellmann, Mark M Awad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2017
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn, David R Spigel, Everett E Vokes, et al.
Journal for Immunotherapy of Cancer
|
February 1, 2023
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 211) with videos related to
Sort By:
Page
of 22
Nature Medicine
|
March 30, 2026
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial
Zev A Wainberg, Gulam A Manji, Nathan Bahary, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2021
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H Hanna, Andrew G Robinson, Sarah Temin, et al.
Clinical Lung Cancer
|
May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
Fred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
Navneet Singh, Sarah Temin, Sherman Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
Navneet Singh, Sarah Temin, Sherman Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
David E Gerber, Jeffrey R Infante, Michael S Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready, Matthew D Hellmann, Mark M Awad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2017
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn, David R Spigel, Everett E Vokes, et al.
Journal for Immunotherapy of Cancer
|
February 1, 2023
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, et al.
Page
of 22